ETPrime

Glenmark Pharmaceuticals Share Price

  • 1,428.90-11.20 (-0.78%)
  • Volume: 1,65,291
  • Live
  • Last Updated On: 22 May, 2025, 12:29 PM IST
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Glenmark Pharmaceuticals Share Price
  • 1,428.90-11.20 (-0.78%)
  • Volume: 1,65,291
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

BUY

Mean Recos by
9 Analysts

0

1

2

2

4

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Glenmark Pharma share price insights

  • Meeting Agenda: Audited Results & Final Dividend. Please add to watchlist to track closely.

  • Company has spent 4.37% of its operating revenues towards interest expenses and 24.28% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • Glenmark Pharmaceuticals Ltd. share price moved down by -0.81% from its previous close of Rs 1,440.10. Glenmark Pharmaceuticals Ltd. stock last traded price is 1,428.50

    Share PriceValue
    Today/Current/Last1,428.50
    Previous Day1,440.101,439.75

InsightsGlenmark Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		-229.86
    EPS - TTM
    (₹)    		-6.23
    MCap
    (₹ Cr.)    		40,409.34
    Sectoral MCap Rank
    		13
    PB Ratio
    (x)    		5.18
    Div Yield
    (%)    		0.17
    Face Value
    (₹)    		1.00
    Beta

    Beta

    1 Month0.56
    3 Months0.53
    6 Months0.69
    1 Year0.83
    3 Years0.91

    		0.56
    VWAP
    (₹)    		1,428.38
    52W H/L
    (₹)
    1,830.95 / 1,000.00

    Glenmark Pharma Share Price Returns

    1 Day-0.78%
    1 Week-1.25%
    1 Month2.74%
    3 Months9.85%
    1 Year39.36%
    3 Years250.65%
    5 Years305.94%

    ET Stock ScreenersTop Score Companies

    Check whether Glenmark Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Glenmark Pharma News & Analysis

    View all Glenmark Pharma Share News & Announcements

    Glenmark Pharma Share Recommendations

    Recent Recos

    BUY

    Current

    Mean Recos by 9 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹1265
    • OrganizationICICI Securities
    • REDUCE
    • Target₹1779
    • OrganizationChoice Equity Broking Private Ltd
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy4444
    Buy2221
    Hold2224
    Sell1111
    Strong Sell----
    # Analysts99910
    View all Stock Recommendations

    Glenmark Pharma Financials

    • Insights

      • Employee & Interest Expense

        Company has spent 4.37% of its operating revenues towards interest expenses and 24.28% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income3,418.683,473.213,275.683,836.122,552.11
      Total Income Growth (%)-1.576.03-14.6150.31-20.47
      Total Expenses2,910.062,952.162,773.763,156.732,939.15
      Total Expenses Growth (%)-1.436.43-12.137.40-8.49
      EBIT508.62521.05501.92679.39-387.04
      EBIT Growth (%)-2.393.81-26.12--
      Profit after Tax (PAT)347.96354.21340.27-1,218.28-351.38
      PAT Growth (%)-1.774.10---
      EBIT Margin (%)14.8815.0015.3217.71-15.17
      Net Profit Margin (%)10.1810.2010.39-31.76-13.77
      Basic EPS (₹)12.3312.5512.06-43.18-12.45
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income2,380.472,719.182,385.192,934.491,623.91
      Total Income Growth (%)-12.4614.00-18.7280.71-28.76
      Total Expenses1,812.521,912.321,751.52-3,443.741,625.81
      Total Expenses Growth (%)-5.229.18-150.86-311.82-11.26
      EBIT567.95806.85633.666,378.23-1.90
      EBIT Growth (%)-29.6127.33-90.07--100.42
      Profit after Tax (PAT)413.80595.06453.734,613.70-20.41
      PAT Growth (%)-30.4631.15-90.17--106.75
      EBIT Margin (%)23.8629.6726.57217.35-0.12
      Net Profit Margin (%)17.3821.8819.02157.22-1.26
      Basic EPS (₹)14.6621.0916.08163.50-0.72
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue12,653.0913,306.9012,471.5810,994.1510,800.57
      Total Revenue Growth (%)-4.916.7013.441.797.22
      Total Expenses11,715.6411,672.5910,769.429,656.229,737.37
      Total Expenses Growth (%)0.378.3911.53-0.838.92
      Profit after Tax (PAT)-1,501.67297.25941.71970.04775.97
      PAT Growth (%)-605.20-68.44-2.9225.01-16.11
      Operating Profit Margin (%)12.3015.2716.2515.4513.53
      Net Profit Margin (%)-12.712.287.658.867.29
      Basic EPS (₹)-53.2210.5333.3734.3827.50
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue9,059.149,206.608,756.217,964.177,319.42
      Total Revenue Growth (%)-1.605.149.958.817.95
      Total Expenses7,128.737,138.866,849.106,094.315,803.33
      Total Expenses Growth (%)-0.144.2312.395.019.34
      Profit after Tax (PAT)5,167.291,208.771,997.791,649.451,354.55
      PAT Growth (%)327.48-39.4921.1221.77-16.49
      Operating Profit Margin (%)27.9727.6626.3228.2226.40
      Net Profit Margin (%)65.4814.7024.5321.7920.17
      Basic EPS (₹)183.1342.8470.8058.4648.00

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets14,358.6219,371.6817,083.2915,603.5814,684.81
      Total Assets Growth (%)-25.8813.409.486.2610.45
      Total Liabilities6,511.089,532.427,645.178,539.308,614.69
      Total Liabilities Growth (%)-31.7024.69-10.47-0.8812.01
      Total Equity7,847.559,839.269,438.127,064.276,070.11
      Total Equity Growth (%)-20.244.2533.6016.388.30
      Current Ratio (x)1.281.961.771.751.65
      Total Debt to Equity (x)0.130.460.400.660.74
      Contingent Liabilities1,193.96477.58559.75544.81437.37
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets27,414.3924,585.9222,914.4820,617.5218,951.60
      Total Assets Growth (%)11.507.2911.148.7910.55
      Total Liabilities4,443.786,708.466,175.905,808.015,725.34
      Total Liabilities Growth (%)-33.768.626.331.4410.09
      Total Equity22,970.6217,877.4616,738.5914,809.5113,226.26
      Total Equity Growth (%)28.496.8013.0311.9710.75
      Current Ratio (x)1.091.201.281.961.85
      Total Debt to Equity (x)0.030.180.220.240.27
      Contingent Liabilities2,658.493,922.953,699.684,012.994,663.26

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities-265.44625.391,108.651,131.211,392.41
      Net Cash used in Investing Activities4,560.89-528.49-333.28-675.24-783.52
      Net Cash flow from Financing Activities-3,906.13-77.46-520.49-441.78-444.66
      Net Cash Flow215.2432.50272.4327.82174.00
      Closing Cash & Cash Equivalent1,658.271,443.031,410.531,138.101,110.28
      Closing Cash & Cash Equivalent Growth (%)14.922.3023.942.5118.58
      Total Debt/ CFO (x)-3.736.953.314.143.22
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities-495.451,474.061,216.071,243.421,579.12
      Net Cash used in Investing Activities3,197.19-431.47-896.92-1,235.23-1,607.38
      Net Cash flow from Financing Activities-2,666.45-978.50-305.12-80.79-139.42
      Net Cash Flow35.2764.0513.93-72.57-167.71
      Closing Cash & Cash Equivalent127.9692.7028.6514.7287.29
      Closing Cash & Cash Equivalent Growth (%)38.05223.5594.59-83.13-65.77
      Total Debt/ CFO (x)-1.332.143.022.922.26

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)-19.133.1310.3613.7312.78
      Return on Capital Employed (%)17.0113.8416.1314.8313.64
      Return on Assets (%)-10.451.535.516.215.28
      Interest Coverage Ratio (x)3.947.428.346.053.82
      Asset Turnover Ratio (x)0.700.710.420.4372.46
      Price to Earnings (x)-18.0244.2513.2613.517.50
      Price to Book (x)3.441.381.371.860.96
      EV/EBITDA (x)12.956.316.077.804.95
      EBITDA Margin (%)17.2219.9720.2119.5017.45
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)22.496.7611.9311.1310.24
      Return on Capital Employed (%)9.5410.8611.0011.7910.70
      Return on Assets (%)18.844.918.718.007.14
      Interest Coverage Ratio (x)8.7011.899.768.606.91
      Asset Turnover Ratio (x)0.300.350.370.3835.41
      Price to Earnings (x)5.2310.866.257.954.29
      Price to Book (x)1.180.730.750.890.44
      EV/EBITDA (x)11.436.587.007.314.87
      EBITDA Margin (%)30.5329.9028.2830.2128.46

    Financial InsightsGlenmark Pharma

    • Income (P&L)

      • Employee & Interest Expense

        Company has spent 4.37% of its operating revenues towards interest expenses and 24.28% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Glenmark Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Glenmark Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Glenmark Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Glenmark Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Glenmark Pharma Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • 46%
      Positive Movement since
      1st Jan 2005 on basis
      54%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic1439.471450.831473.331428.331416.971405.831383.33

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR36.4643.4546.55

    Glenmark Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Glenmark Pharma-229.495.14-19.1317.01-10.454.7512.30-12.13-53.221.280.13-3.73
          Biocon39.541.454.686.041.7224.9017.609.368.461.140.824.37
          Ipca Labs50.514.778.6412.444.9312.4814.126.8625.822.350.221.47
          Ajanta Pharma35.508.6224.2830.1018.3511.0026.0219.8073.562.850.000.00
          Laurus Labs88.026.858.0112.083.834.3412.606.386.651.220.604.48
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Piramal Pharma
          • Suven Pharma
          • J B Chemicals
          • Syngene Int.
          • Gland Pharma

          Choose from Stocks

            See All Parameters

          Peers InsightsGlenmark Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Glenmark Pharma Shareholding Pattern

            • Loading...
              Showing Glenmark Pharma Shareholding as on Mar 2025
              CategoryMar 2025Dec 2024Sep 2024Jun 2024
              Promoters46.6546.6546.6546.65
              Pledge0.000.000.000.00
              FII23.1523.5123.0520.98
              DII14.6013.8513.2113.85
              Mutual Funds12.8612.1211.4110.92
              Others15.6015.9917.0918.52
            • Showing Shareholding as on Mar 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters13,16,32,93746.65 %0.00
              Pledge00.00 %0.00
              FII6,53,50,74323.15 %-0.35
              DII4,11,94,00214.60 %0.75
              MF3,62,91,33712.86 %0.74
              Others4,40,10,47415.60 %-0.39

            Glenmark Pharma MF Ownership

            MF Ownership as on 30 April 2025

            View all Mutual Fund Schemes
            Top Searches:
            Glenmark Pharma News Glenmark Pharma Quarterly Results Glenmark Pharma Dividend Glenmark Pharma Q1 ResultsGlenmark Pharma Q2 ResultsGlenmark Pharma Q3 ResultsGlenmark Pharma Q4 Results

            Glenmark Pharma F&O Quote

              • Expiry

              Price

              1,436.00-4.40 (-0.31%)

              Open Interest

              63,41,07550,055 (0.80%)

              OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
              1,443.001,443.001,418.501,440.402914,172.99

              Open Interest as of 22 May 2025

              • Type
              • Expiry
              • Strike Price

              Price

              30.90-4.65 (-13.08%)

              Open Interest

              3,55,55020,800 (6.21%)

              OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
              32.6533.7527.0035.551422,088.31

              Open Interest as of 22 May 2025

            Glenmark Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              May 23, 2025May 12, 2025Board MeetingAudited Results & Final Dividend
              Apr 27, 2025Mar 26, 2025POM-
              Feb 14, 2025Feb 03, 2025Board MeetingQuarterly Results
              Nov 14, 2024Oct 30, 2024Board MeetingQuarterly Results
              Sep 27, 2024Aug 30, 2024AGMRs.2.5000 per share(250%)Final Dividend & A.G.M.
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Final250%2.5Sep 13, 2024May 24, 2024
              Final250%2.5Sep 18, 2023May 19, 2023
              Final250%2.5Sep 12, 2022May 30, 2022
              Final250%2.5Sep 08, 2021May 28, 2021
              Final250%2.5Sep 17, 2020Jun 26, 2020
            • All TypesEx-DateRecord DateAnnounced onDetails
              SplitsSep 10, 2007-Jun 11, 2007Split: Old FV2.0| New FV:1.0
              BonusMar 04, 2005-Jan 06, 2005Bonus Ratio: 1 share(s) for every 1 shares held
              SplitsOct 23, 2003Oct 31, 2003Jul 31, 2003Split: Old FV10.0| New FV:2.0

            About Glenmark Pharma

            Glenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 40,637.92 Crore) operating in Pharmaceuticals sector. Glenmark Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the year ending 31-Mar-2023. Show More

            • Executives

            • Auditors

            • GS

              Glenn Saldanha

              Chairman & Managing Director
              VS

              V S Mani

              Executive Director & Global CFO
              CP

              Cherylann Pinto

              Executive Director - Corporate Affairs
              BE

              B E Saldanha

              Non Executive Director
              Show More
            • Suresh Surana & Associates LLP
              Walker, Chandiok & Co.LLP

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty Midcap 100, Nifty 200, Nifty 500, + 24 more

            Address

            B/2, Mahalaxmi Chambers,22, Bhulabhai Desai Road,Mumbai, Maharashtra - 400026

            Contact

            [email protected]

            http://www.glenmarkpharma.com

            More Details

            FAQs about Glenmark Pharma share

            • 1. What's Glenmark Pharma share price today and what are Glenmark Pharma share returns ?
              Glenmark Pharma share price is Rs 1,433.60 as on 22 May, 2025, 12:03 PM IST. Glenmark Pharma share price is down by 0.46% based on previous share price of Rs. 1436.2. In last 1 Month, Glenmark Pharma share price moved up by 3.08%.
            • 2. What's the market capitalization of Glenmark Pharma?
              Market Capitalization of Glenmark Pharma stock is Rs 40,375.48 Cr.
            • 3. What has been highest price of Glenmark Pharma share in last 52 weeks?
              52 Week high of Glenmark Pharma share is Rs 1,830.95 while 52 week low is Rs 1,000.00
            • 4. What are the Glenmark Pharma quarterly results?
              On Consoldiated basis, Glenmark Pharma reported a total income and loss of Rs 3418.68 Cr and Rs 347.96 respectively for quarter ending 2024-12-31. Total Income and loss for the year ending 2024-03-31 was Rs 12653.09 Cr and Rs -1501.67 Cr.
            • 5. What are the returns for Glenmark Pharma share?
              Return Performance of Glenmark Pharma Shares:
              • 1 Week: Glenmark Pharma share price moved down by 0.93%
              • 1 Month: Glenmark Pharma share price moved up by 3.08%
              • 3 Month: Glenmark Pharma share price moved up by 10.21%
              • 6 Month: Glenmark Pharma share price moved down by 3.02%
            • 6. What is the PE & PB ratio of Glenmark Pharma?
              The PE ratio of Glenmark Pharma stands at -231.11, while the PB ratio is 5.18.
            • 7. Which are the key peers to Glenmark Pharma?
              Top 10 Peers for Glenmark Pharma are Ipca Laboratories Ltd., Biocon Ltd., Laurus Labs Ltd., Ajanta Pharma Ltd., Piramal Pharma Ltd., Syngene International Ltd., Cohance Lifesciences Ltd., Wockhardt Ltd., J B Chemicals & Pharmaceuticals Ltd. and Gland Pharma Ltd.
            • 8. What are the key metrics to analyse Glenmark Pharma Share Price?
              Key Metrics for Glenmark Pharma are:
              • PE Ratio of Glenmark Pharma is -229.49
              • Price/Sales ratio of Glenmark Pharma is 2.29
              • Price to Book ratio of Glenmark Pharma is 5.18
            • 9. What is the CAGR of Glenmark Pharma?
              The CAGR of Glenmark Pharma is 1.93.
            • 10. Who's the chairman of Glenmark Pharma?
              Glenn Saldanha is the Chairman & Managing Director of Glenmark Pharma
            • 11. Who's the owner of Glenmark Pharma?
              Following are the key changes to Glenmark Pharma shareholding:
              • Promoter holding has not changed in last 9 months and holds 46.65 stake as on 31 Mar 2025
              • Domestic Institutional Investors holding has gone up from 13.85 (30 Jun 2024) to 14.6 (31 Mar 2025)
              • Foreign Institutional Investors holding has gone up from 20.98 (30 Jun 2024) to 23.15 (31 Mar 2025)
              • Other investor holding have gone down from 18.52 (30 Jun 2024) to 15.6 (31 Mar 2025)
            • 12. What dividend is Glenmark Pharma giving?
              Glenmark Pharmaceuticals Ltd. announced an equity dividend of 250% on a face value of 1.0 amounting to Rs 2.5 per share on 24 May 2024. The ex dividend date was 13 Sep 2024.

            Trending in Markets

            Top Gainers As on 12:26 PM | 22 May 2025

            Tata Teleservices78.59
            9.50 (13.76%)
            Fortis Healthcare734.95
            62.91 (9.36%)
            SCI195.80
            14.00 (7.71%)
            GRSE2,656.90
            156.41 (6.26%)
            Craftsman Automation5,585.20
            286.50 (5.41%)

            Top Losers As on 12:24 PM | 22 May 2025

            Aditya Birla Retail89.90
            -179.05 (-66.58%)
            Colgate-Palmolive2,533.20
            -126.11 (-4.75%)
            Redington276.92
            -12.96 (-4.48%)
            Mankind Pharma2,440.00
            -91.41 (-3.62%)
            BSE7,042.00
            -263.00 (-3.61%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Glenmark Pharma Share Price
            The Economic Times
            BrowseCompanies:
            OSZAR »